Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric caspofungin study for Candida or Aspergillus infections
2014-004911-35Phase 2
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in invasive aspergillosis (IA), invasive candidiasis and Candida esophagitis, sponsored by Merck & Co. Primary endpoint: Proportion of pediatric patients with one or more drug-related clinical or laboratory adverse experiences.
02
Drugs
caspofungin
03
Conditions
invasive aspergillosis (IA)invasive candidiasisCandida esophagitis
Beyond the preview
Go deeper on 2014-004911-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004911-35.